Search bioRxiv⌕ Search

Biology subjects

Le Gac, G.

Publications and source records attributed to Le Gac, G..

3 recordsLinked to original sources

Insights into the role of glycerophospholipids on the iron export function of SLC40A1 and the molecular mechanisms of ferroportin disease.

SLC40A1 is the sole iron export protein reported in mammals. In humans, its dysfunction is responsible for ferroportin disease, an inborn error of iron metabolism transmitted as an autosomal dominant trait and observed in different ethnic groups. As a member of the major facilitator superfamily, SLC40A1 requires a series of conformational changes to enable iron translocation across the plasma membrane. The influence of lipids on these conformational changes has been little investigated to date. Here, we combine molecular dynamics simulations of SLC40A1 embedded in bilayers with experimental alanine scanning mutagenesis to analyze the specific role of glycerophospholipids. We identify four basic residues (Lys90, Arg365, Lys366 and Arg371) that are located at the membrane-cytosol interface and consistently interact with POPC and POPE lipid molecules. These residues surround a network of salt bridges and hydrogens bonds that play a critical role in stabilizing SLC40A1 in its basal outward-facing conformation. More deeply embedded in the plasma membrane, we identify Arg179 as a charged amino acid residue also tightly interacting with lipid phosphates. This result into a local deformation of the lipid bilayer. Interestingly, Arg179 is adjacent to Arg178, which forms a functionally important salt-bridge with Asp473 and is a recurrently associated with ferroportin disease when mutated to glutamine. We demonstrate that the two p.Arg178Gln and p.Arg179Thr missense variants have similar functional behaviors. These observations provide insights into the role of phospholipids in the formation/disruption of the SLC40A1 inner gate, and give a better understanding of the diversity of molecular mechanisms of ferroportin disease.

molecular biology↗

Cholesterol modulates the human FPN1 iron export function in plasma membrane liquid-ordered microdomains

Ferroportin 1 (FPN1) is the only known mammalian iron efflux transporter. This multi-pass membrane protein, which adopts the Major Facilitator Superfamily fold, is tightly controlled by serum hepcidin to assure maintenance of adequate cellular and systemic iron levels. Earlier studies have shown that cholesterol-lowering drugs can reduce FPN1 expression in liquid-ordered plasma membrane microdomains and its sensitivity to hepcidin. However, the molecular mechanism by which cholesterol depletion regulates the localization of FPN1 at the cell surface remains unknown. In biochemical experiments, we show that cholesterol depletion reduces the iron export function of FPN1. Repletion with cholesterol restores FPN1 activity. This is not observed with the diastereoisomer epicholesterol, suggesting a direct interaction between cholesterol and FPN1. Consistent with this, we demonstrate that mutants affecting the key tyrosine residues of three cholesterol-recognition amino acid consensus (CRAC/CARC) motifs have a negative impact on FPN1 activity, in manner that also decreases its abundance in ordered plasma membrane microdomains. A complementary structural analysis allows us to focus on a conserved CARC motif (CARC-1) located in a deep hydrophobic groove between transmembrane helices 1 and 5. Molecular docking suggests that this groove is well suited to cholesterol binding. All these findings indicate that the interaction between FPN1 and cholesterol is of major importance for the localization of FPN1 in ordered microdomains of the plasma membrane, which is necessary for its optimal activity, and so its responsiveness to hepcidin.

biochemistry↗

First estimation of the scale of canonical 5’ splice site GT>GC mutations generating wild-type transcripts and their medical genetic implications

It has long been known that canonical 5 splice site (5SS) GT>GC mutations may be compatible with normal splicing. However, to date, the true scale of canonical 5SS GT>GC mutations generating wild-type transcripts, both in the context of the frequency of such mutations and the level of wild-type transcripts generated from the mutation alleles, remain unknown. Herein, combining data derived from a meta-analysis of 45 informative disease-causing 5SS GT>GC mutations (from 42 genes) and a cell culture-based full-length gene splicing assay of 103 5SS GT>GC mutations (from 30 genes), we estimate that [~]15-18% of the canonical GT 5SSs are capable of generating between 1 and 84% normal transcripts as a consequence of the substitution of GT by GC. We further demonstrate that the canonical 5SSs whose substitutions of GT by GC generated normal transcripts show stronger complementarity to the 5 end of U1 snRNA than those sites whose substitutions of GT by GC did not lead to the generation of normal transcripts. We also observed a correlation between the generation of wild-type transcripts and a milder than expected clinical phenotype but found that none of the available splicing prediction tools were able to accurately predict the functional impact of 5SS GT>GC mutations. Our findings imply that 5SS GT>GC mutations may not invariably cause human disease but should also help to improve our understanding of the evolutionary processes that accompanied GT>GC subtype switching of U2-type introns in mammals.

genetics↗